Aerie Pharma (NASDAQ:AERI) reported Q2 EPS of ($0.32), $0.24 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $33 million versus the consensus estimate of $32.49 million.
Aerie Pharma (NASDAQ:AERI) reported Q2 EPS of ($0.32), $0.24 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $33 million versus the consensus estimate of $32.49 million.